HC Wainwright & Co. Maintains Buy on BridgeBio Pharma, Raises Price Target to $110

Benzinga Newsdesk www.benzinga.com Positive 80.6%

Neg 0% Neu 0% Pos 80.6%

HC Wainwright & Co. analyst Raghuram Selvaraju maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $100 to $110.